Representative Kevin Hern (Republican-Oklahoma) recently sold shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on September 3rd. The trade occurred in the Representative’s “KADEN EVERETT HERN TRUST” account.
Representative Kevin Hern also recently made the following trade(s):
- Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
- Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
- Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
- Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
- Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
- Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
- Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
- Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
- Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
- Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.
IQVIA Stock Down 1.6%
Shares of IQV stock traded down $4.38 on Tuesday, reaching $266.58. 124,975 shares of the stock were exchanged, compared to its average volume of 1,724,784. The company has a market capitalization of $43.88 billion, a price-to-earnings ratio of 33.11, a PEG ratio of 2.31 and a beta of 1.18. The business’s 50 day moving average price is $250.32 and its 200 day moving average price is $203.63. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $277.40.
Hedge Funds Weigh In On IQVIA
A number of large investors have recently modified their holdings of IQV. Apella Capital LLC increased its holdings in IQVIA by 5.1% during the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after acquiring an additional 58 shares in the last quarter. Breakwater Capital Group raised its holdings in IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after acquiring an additional 64 shares during the last quarter. First Growth Capital LLC lifted its stake in shares of IQVIA by 3.2% during the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after purchasing an additional 68 shares during the period. Root Financial Partners LLC boosted its holdings in shares of IQVIA by 31.0% during the fourth quarter. Root Financial Partners LLC now owns 296 shares of the medical research company’s stock worth $67,000 after purchasing an additional 70 shares during the last quarter. Finally, Chicago Partners Investment Group LLC grew its position in shares of IQVIA by 1.5% in the first quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock valued at $812,000 after purchasing an additional 70 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
IQV has been the topic of several research analyst reports. Barclays reissued an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, September 12th. Royal Bank Of Canada raised their price objective on shares of IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a report on Tuesday. Morgan Stanley upped their target price on shares of IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, September 17th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $329.00 target price (up from $300.00) on shares of IQVIA in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $257.75.
Read Our Latest Stock Analysis on IQV
Insider Activity
In other IQVIA news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares in the company, valued at $2,845,883.70. The trade was a 19.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider W. Richard Staub sold 5,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 in the last three months. Company insiders own 1.70% of the company’s stock.
About Representative Hern
Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.
Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.
Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.
About IQVIA
IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.
IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.
Featured Stories
- Five stocks we like better than IQVIA
- Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown
- Meta’s Muse Is Taking Aim at E-Commerce, But Amazon Isn’t Playing Along
- NVIDIA Just Strengthened the Case for Its Massive Stock Price Upside
- Apple, Meta, and SpaceX Are Driving a Device Boom—These 3 Stocks Could Benefit
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
